deflazacort has been researched along with atropine in 3 studies
| Studies (deflazacort) | Trials (deflazacort) | Recent Studies (post-2010) (deflazacort) | Studies (atropine) | Trials (atropine) | Recent Studies (post-2010) (atropine) |
|---|---|---|---|---|---|
| 452 | 99 | 115 | 26,711 | 1,259 | 1,697 |
| Protein | Taxonomy | deflazacort (IC50) | atropine (IC50) |
|---|---|---|---|
| cystic fibrosis transmembrane conductance regulator | Homo sapiens (human) | 21.41 | |
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 1.012 | |
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | 0.0067 | |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 0.0007 | |
| Muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | 0.001 | |
| Muscarinic acetylcholine receptor M3 | Rattus norvegicus (Norway rat) | 0.001 | |
| Muscarinic acetylcholine receptor M4 | Rattus norvegicus (Norway rat) | 0.001 | |
| Muscarinic acetylcholine receptor M5 | Rattus norvegicus (Norway rat) | 0.001 | |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | 0.0009 | |
| Muscarinic acetylcholine receptor M2 | Rattus norvegicus (Norway rat) | 0.001 | |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | 0.0015 | |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | 0.0021 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 1.354 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 1.012 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Adame, M; Calderón, R; Fernández-Liesa, JI; Mendieta, JM; Muñoz, C; Panadero, A | 1 |
3 other study(ies) available for deflazacort and atropine
| Article | Year |
|---|---|
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
[Common variable immunodeficiency associated with autoimmune thrombocytopenia: anesthetic management].
Topics: Adjuvants, Anesthesia; Adult; Aminocaproic Acid; Androstanols; Anesthesia, Inhalation; Anesthetics; Atropine; Autoimmune Diseases; Bromazepam; Combined Modality Therapy; Common Variable Immunodeficiency; Fentanyl; Fissure in Ano; Granulocyte Colony-Stimulating Factor; Hemorrhoids; Humans; Hypnotics and Sedatives; Immunoglobulins, Intravenous; Laryngeal Masks; Male; Methyl Ethers; Nitrous Oxide; Platelet Transfusion; Postoperative Complications; Preanesthetic Medication; Pregnenediones; Propofol; Purpura, Thrombocytopenic, Idiopathic; Ranitidine; Rocuronium; Sevoflurane; Thrombocytopenia | 1998 |